Infectious Disease

ACE inhibitors and ARBs don’t signify a further threat for COVID-19 in two meta-analyzes

December 04, 2020

2 min read

Source / information

Source:

Yokoyama Y et al. COVID-19: Risk Assessments and Risk Factors for Adverse Results. Presented at: American Heart Association Scientific Sessions; 13-17 November 2020 (virtual meeting).

Disclosure:
Yokoyama does not report any relevant financial information. In the study you will find all relevant financial information from all other authors.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

The use of ACE inhibitors and angiotensin receptor blockers was not associated with increased rates of COVID-19 infections or mortality, according to two meta-analyzes reported at the American Heart Association’s virtual scientific sessions.

Yujiro Yokoyama, MD, a surgeon at St. Luke’s University Health Network’s Easton Hospital in Bethlehem, Pennsylvania, and colleagues performed two meta-analyzes to compare mortality and susceptibility to COVID-19 infection between patients treated with ACE inhibitors and / or treated with angiotensin and untreated receptor blockers. In the first meta-analysis the influence of positive COVID-19 tests on the rate and in the second meta-analysis the influence of COVID-19 on mortality in the hospital was assessed.

Source: Adobe Stock

The researchers examined MEDLINE and EMBASE databases to identify studies detailing patients treated with ACE inhibitors and / or angiotensin receptor blocks. Your search returned three eligible studies for the first meta-analysis and 14 eligible studies for the second meta-analysis.

The positive COVID-19 test rates were in patients treated with ACE inhibitors compared to patients who did not receive ACE inhibitors (OR = 0.96; 95% CI, 0.88-1.04; P. = 0.69), and in patients treated with angiotensin receptor blockers, similarly to those not treated with angiotensin receptor blockers (OR = 0.99; 95% CI, 0.91-1.08; P = 0.35 ), according to the summary.

In-hospital mortality rates in patients who tested positive for COVID-19 infection were similar between patients treated with ACE inhibitors and / or angiotensin receptor blockers and those who did not receive either drug (HR = 0 , 88; 95% CI, 0.64-1.2); P = .42) according to the summary.

In a sub-analysis limited to studies examining only patients with hypertension, the use of ACE inhibitors and / or angiotensin receptor blockers was associated with a significant reduction in hospital mortality compared to no use of medication (HR = 0 , 65; 95% CI, 0.48-0.87), according to the abstract.

“Our study results confirm that patients who are already taking ACE inhibitors and angiotensin receptor blockers should not stop taking them because of COVID-19 infection,” Yokoyama said in a press release. “Both drugs have been shown to be beneficial for heart and kidney disease, and this confirms previous findings that ACE inhibitors do not pose an additional risk with COVID-19.”

Earlier this year, the AHA, the Heart Failure Society of America, and the American College of Cardiology issued a joint statement calling for the continuation of ACE inhibitors and angiotensin receptor blockers in patients treated with these drugs during the COVID-19 pandemic HF, hypertension, and / or ischemic heart disease have been prescribed and recommended that patients with COVID-19 should be fully evaluated prior to any change in treatment.

Reference:

Press release.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

American Heart Association

American Heart Association

Related Articles